glp-1 news nov 2025 What's next for innovation: A primer on the race reshaping pharma and chronic disease care November in review: GLP-1 breakthroughs,

There is no physiological reason you cannot alternate between protocols

Oral tirzepatide is in clinical trials, and if successful, could eliminate the injection barrier entirely for this class

The information obtained by using these technologies (including, but not limited to, the pages you visit on our website, which web address you came from, information about the devices and software you use, and the content you view) helps us in various ways, including, but not limited to, to customize your experience, improve the Services, learn what areas of the Services are of most interest to our customers, and troubleshoot any issues

For those looking to achieve and maintain weight loss, GLP-1 medications offer a promising option to support long-term success

In the SELECT trial, which included more than 17,000 patients with obesity and cardiovascular disease but not diabetes, semaglutide cut the rate of major cardiac events by 20%

Int J Mol Med 2017;39:102936.ArticlePubMed 57